Medscape

Novel Treatments for Cutaneous Neurofibromas Show Promise

In the opinion of R. Rox Anderson, MD, patients with neurofibromatosis type 1 (NF1) have long been underserved in the medical field. Affected children are born with café-au-lait spots and sometimes ...
Morningstar

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

MIAMI, May 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation ...
Business Wire

Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of Neurofibromatosis Type 1

CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company dedicated to rare diseases, today announced the first patient has been dosed in INSPIRE-NF1, a Phase 2 trial ...
Nasdaq

Pasithea Therapeutics Initiates Phase 1/1b Clinical Trial for PAS-004 in Adult Patients with Neurofibromatosis Type 1

Pasithea Therapeutics initiates Phase 1/1b trial of PAS-004 for neurofibromatosis type 1, aiming for patient dosing in Q2 2025. Pasithea Therapeutics Corp. has announced the initiation of a Phase 1/1b ...
Nasdaq

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation ...